ESSA Pharma Inc.
DelistedCIK 1633932fmd_1N1C36XHN3D1SQ6GGN1W4TE8CTManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2015 to Jun 30, 2025, 27 periods
Latest annual · FY2024
Millions- Net income
- (29)
Latest quarter · Q3 FY2025
Millions- Net income
- (4)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2019 to FY2024
- n/m
ESSA Pharma Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Net income | -$28.5 million | -$26.6 million | 10-K 2024-12-17 · proof | |
| Cash from operating activities | -$22.7 million | -$19.8 million | 10-K 2024-12-17 · proof | |
| Total assets | $128.1 million | $149.1 million | -14.1% | 10-K 2024-12-17 · proof |
| Total liabilities | $3.5 million | $3.5 million | +0.3% | 10-K 2024-12-17 · proof |
| Cash and cash equivalents | $103.7 million | $33.7 million | +207.7% | 10-K 2024-12-17 · proof |
- What was ESSA Pharma Inc.'s net income in fiscal 2024?
- ESSA Pharma Inc. reported net income of -$28.5 million for fiscal 2024 (the year ended Sep 30, 2024), against -$26.6 million the year before. Source: the 10-K filed with the SEC on Dec 17, 2024. SEC
- What was ESSA Pharma Inc.'s cash from operating activities in fiscal 2024?
- ESSA Pharma Inc. reported cash from operating activities of -$22.7 million for fiscal 2024 (the year ended Sep 30, 2024), against -$19.8 million the year before. Source: the 10-K filed with the SEC on Dec 17, 2024. SEC
- What are ESSA Pharma Inc.'s total assets?
- As of Sep 30, 2024, ESSA Pharma Inc. reported total assets of $128.1 million, against $149.1 million a year earlier (-14.1%). Source: the 10-K filed with the SEC on Dec 17, 2024. SEC
- What are ESSA Pharma Inc.'s total liabilities?
- As of Sep 30, 2024, ESSA Pharma Inc. reported total liabilities of $3.5 million, against $3.5 million a year earlier (+0.3%). Source: the 10-K filed with the SEC on Dec 17, 2024. SEC
- What are ESSA Pharma Inc.'s cash and cash equivalents?
- As of Sep 30, 2024, ESSA Pharma Inc. reported cash and cash equivalents of $103.7 million, against $33.7 million a year earlier (+207.7%). Source: the 10-K filed with the SEC on Dec 17, 2024. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1633932&period_type=annual&limit=5"Information only, not investment advice.